reSee.it - Related Video Feed

People are delaying pregnancy, with fertility rates declining. Women are born with 1 to 2 million eggs, but by age 35, their chances of conception decrease significantly. Dr. Natalie Crawford, a fertility expert, highlights the rising infertility rates, now affecting one in five women in the U.S. Factors include delayed childbearing, obesity, autoimmune diseases, and chronic stress. At age 40, the chance of miscarriage is 50%, which can lead to emotional distress, as Crawford experienced through her own pregnancy losses. Crawford emphasizes the importance of understanding reproductive health early. Many women lack knowledge about their bodies, leading to regrets later in life. Fertility should be viewed as a health marker, similar to other diseases. Social media has increased awareness of infertility, but many still struggle in silence. The decline in fertility rates is compounded by lifestyle factors, including increased obesity and environmental toxins. Crawford discusses sperm health, noting that sperm counts have decreased by 50% over the last 50 years. Men produce sperm continuously, while women have a finite number of eggs. Lifestyle choices, such as smoking and excessive heat exposure, can negatively impact sperm production. Regular ejaculation is important for maintaining sperm health. The concept of the "vault" illustrates women's egg reserves. Women lose eggs monthly, and by age 30, the number of eggs released decreases significantly. Factors like smoking and environmental toxins can accelerate egg loss and affect quality. Understanding ovarian reserve through tests like AMH can help women make informed decisions about family planning. Crawford addresses the stigma surrounding infertility treatments, encouraging open conversations about fertility. Many women feel guilty or broken when facing reproductive challenges. She advocates for proactive measures, such as egg freezing, especially for those not ready to conceive but wanting to preserve fertility. Diet and lifestyle play crucial roles in reproductive health. A balanced diet rich in fruits and vegetables, adequate sleep, and stress management can improve fertility. Chronic stress and inflammation can disrupt hormonal balance, impacting both men and women. Crawford highlights the importance of regular menstrual cycles as indicators of reproductive health. Irregular cycles can signal underlying issues like PCOS or endometriosis, which can complicate conception. Endometriosis affects 10% of women and is often undiagnosed, leading to infertility. For couples struggling to conceive, Crawford recommends seeking second opinions and being proactive in understanding their reproductive health. She emphasizes that infertility is not a personal failure and encourages individuals to seek support and information. Crawford shares her personal experiences with pregnancy loss, underscoring the emotional toll of infertility. She encourages patients to remain hopeful and informed, emphasizing that understanding one's body and making educated choices can lead to better outcomes in family planning.

The episode centers on the launch of Nucleus Embryo, a genetic optimization platform that analyzes embryo DNA to provide a full profile of potential diseases, traits, and risks, including cancers, IQ, eye color, and schizophrenia. Keon explains that the service enables couples with multiple viable embryos to upload DNA files and receive comprehensive analyses, allowing them to compare and select embryos with preferences in mind. The conversation situates this tool within a broader preventive medicine vision and introduces the idea of generational health, where genetic testing spans preconception, conception, and post-birth phases. Keon ties the technology to a growing reproductive stack that bridges adult DNA testing with embryonic analysis, and stresses patient empowerment by removing gatekeeping from doctors who historically control what information couples access about their future children. The discussion also delves into the practical realities of IVF, noting rising usage, cost considerations, and the rapid decrease in genome sequencing costs, which together could broaden access to genetically informed parenting. Throughout, the host and guest emphasize that DNA is not destiny and frame genetic analysis as one tool among many in medical decision-making, while advocating transparency, education, and patient ownership of results. They address model limitations, acknowledging that predictions vary in reliability depending on how much a trait is genetically determined, and they contrast embryo selection with disease-focused fertility clinic testing, arguing that a broader, more information-rich approach can guide healthier, well-informed choices for families. The interview concludes with reflections on industry implications, consumer education, and the potential for the technology to become ubiquitous, along with forward-looking notes on sequencing, genome editing, and the ethical frameworks that should guide responsible use.

In this episode of The Drive Podcast, Peter Attia and Paula Amato discuss female fertility, emphasizing the unique physiological aspects compared to male fertility. Women are born with a finite number of eggs, peaking at around two million in the womb, and decreasing to about 400,000 by puberty. Each month, a group of eggs begins to mature, but typically only one is released during ovulation. Hormones like follicle-stimulating hormone (FSH) and luteinizing hormone (LH) play crucial roles in this process. Attia and Amato highlight the importance of early intervention for women considering pregnancy, particularly those in their 20s who may want to freeze their eggs. They discuss the impact of lifestyle factors, such as exercise and stress, on fertility. Extreme exercise can disrupt menstrual cycles, while maintaining a healthy weight and diet is beneficial. The Mediterranean diet is recommended for its overall health benefits. The conversation shifts to assisted reproductive technologies, particularly in vitro fertilization (IVF). IVF involves several steps: ovarian stimulation with hormones, egg retrieval, fertilization, and embryo culture. The success rates of IVF vary significantly based on factors like maternal age and egg quality. Genetic testing of embryos is becoming standard practice, allowing for the selection of chromosomally normal embryos, which have higher implantation success rates. Amato explains the process of egg retrieval, which is performed under sedation and guided by ultrasound. The retrieved eggs are fertilized either through conventional IVF or intracytoplasmic sperm injection (ICSI), where a single sperm is injected into an egg. The embryos are then cultured for several days before being assessed for viability and potential genetic abnormalities. The discussion also touches on the emotional and psychological aspects of fertility treatments, emphasizing the importance of communication and support for patients. Attia and Amato address the rising rates of infertility, attributing it to factors like delayed childbearing and environmental influences. They encourage women to monitor their menstrual cycles and seek medical advice if they experience irregularities. Looking to the future, Amato mentions promising research areas, including the potential for extending fertility through medications like rapamycin and advancements in genetic testing and embryo selection. The conversation concludes with a call for better awareness and education around fertility issues, particularly for younger women, to help them make informed decisions about their reproductive health.

Certain foods like nuts, dates, and red wine can create a more favorable internal environment for implantation. Infertility is rising, primarily due to age-related factors, with older individuals facing decreased chances of success. Early interventions, such as egg and sperm freezing, can significantly enhance future fertility prospects. Embryo freezing is also an option for couples planning for children later. While age affects egg and sperm quality, the uterus can still support pregnancy later in life with hormone treatments. Men over 40 may experience declining sperm quality, and lifestyle factors like obesity can further impair fertility. Semen analysis can assess sperm quality through volume, concentration, motility, and morphology. Diet plays a crucial role in fertility; a Mediterranean diet is recommended for its health benefits. Foods that promote implantation include warming foods, while cold foods may hinder it. Vegan diets can pose challenges, but legumes and nuts can help mitigate nutrient deficiencies. Misconceptions about IVF persist, with many believing it guarantees pregnancy. Egg freezing is best considered before age 30, although options remain for older individuals. Costs vary, with egg freezing generally more expensive than sperm freezing, and ongoing storage fees apply. The clinic offers resources and support for individuals navigating fertility challenges, emphasizing the importance of lifestyle and diet in optimizing reproductive health.

An old morality tale about a 'defective' child reappears in today’s biotech world, where Silicon Valley promises to design healthier or smarter babies. The Black Stork warned against hereditary risk, and this transcript traces a contemporary echo: embryo testing and selection offered by Orchid and similar startups, with Nor Sadiki describing how IVF embryos are analyzed for health, IQ, hair color, and other traits. The interview notes that the New York Times covered a tech founder backed by Peter Thiel to develop these offerings, and mentions Elon Musk among rumored clients. The argument presented is that parents can, and perhaps should, identify embryos with lower genetic risk and transfer those with the best chances of a healthy life, a stance presented as a positive moral choice rather than a taboo. Advocates frame this as progress, while critics warn of a new eugenics ecosystem driven by markets, wealth, and status. The conversation expands to immigration policy, white-nationalist rhetoric, and the danger of a rigid genetic hierarchy, echoed in references to Gatka and broader fears about AI and future inequality.

Dov Fox, a law professor and bioethics expert, discusses his new book, *Birth Rights and Wrongs: How Medicine and Technology Are Remaking Reproduction and the Law*, and his podcast, *Donor 9623*, which explores the story of a sperm donor who misrepresented himself. Fox, a Rhodes Scholar with a background in law and political philosophy, shares his personal experiences growing up in a complex family dynamic after his parents' separation and his father's struggles with alcoholism. The conversation delves into the implications of sperm donation, particularly focusing on the case of Donor 9623, who was marketed as an ideal donor with impressive credentials, but whose true background revealed serious mental health issues. Fox highlights the lack of regulation in the sperm donation industry, where donors are not adequately vetted, leading to potential risks for families relying on these services. He notes that one in 50 children in the U.S. are conceived through assisted reproductive technologies, a statistic that may surprise many. Fox emphasizes the ethical dilemmas surrounding genetic selection and the societal implications of eugenics, contrasting historical forced sterilization practices with modern parental choices in donor selection. He argues that while parents may seek to enhance their children's genetic traits, this raises complex moral questions about the nature of parenting and the role of luck in life outcomes. The discussion also touches on the emotional challenges faced by families when discovering unexpected truths about their donor's background, and how these revelations can reshape their understanding of identity and family. Fox advocates for a more regulated approach to the fertility industry, suggesting that the legal system needs to catch up with the advancements in reproductive technology to protect families and ensure ethical practices.

Tucker Carlson hosts a discussion with a biotech entrepreneur about how preimplantation genetic testing and embryo selection work, and what it could mean for families who want to reduce disease risk or customize traits in their future children. The guest explains that IVF creates multiple embryos, which are screened for chromosomal abnormalities and disease risks, and that the additional data provided by newer genetic insights can inform which embryo parents choose to implant. They emphasize that no DNA is edited in this process; instead, information about inherited risks and traits is read to help families select embryos they deem best according to their values and circumstances. The conversation shifts to whether such screening touches on eugenics, with careful attempts to distinguish the concept from controlling reproduction in a coercive or discriminatory way. The participants discuss the historical misuse of eugenics, the difference between improving biological characteristics and moral virtue, and the idea that virtue resides beyond biology. They explore how people’s decisions about embryo selection could reflect personal suffering and family history, including diseases like Huntington’s, cystic fibrosis, or schizophrenia, and they acknowledge that genetic risk is probabilistic and interacts with environment. The dialogue surveys broader implications: the role of centralized power in regulating or steering reproductive choices, the potential for unintended consequences, and the balance between alleviating suffering and preserving moral agency. Throughout, the speakers reference religions and philosophy, debating natural versus divine virtue, and contemplating how a society should constrain or guide technology to align with spiritual and ethical considerations. They acknowledge that technology is not fate, and that responsible stewardship—humility, transparency, and robust dialogue with doctors and patients—matters as much as scientific capability. The episode closes with reflections on the limits of biology in defining worth or virtue, the importance of recognizing the non-deterministic nature of genetic outcomes, and the need to weigh potential benefits against risks while keeping the spiritual dimension in view as a guardrail for future developments.

The episode centers on cryonics, explained by Dr. Max More of Alcor, a nonprofit organization that preserves people after legal death with the aim of possible future revival. Cryonics, the preservation at about minus 320 Fahrenheit, follows the distinction that it is not cryogenics (the engineering of low temperatures) and not simply cryobiology (the study of cold effects). The premise is to keep tissues viable until future technology might repair whatever killed them. Preservation begins at the point of legal death, ideally with the medical team at the bedside, and proceeds through rapid stabilization and careful cooling to maximize viability for revival. During stabilization, the patient is moved to an ice bath, covered with ice and water, a mechanical CPR device operates, and a respirator takes over breathing. Medications are administered, notably propofol to slow brain metabolism and prevent any return to consciousness, plus anticoagulants and other drugs to prevent clotting and support blood pressure. After stabilization, the patient is perfused: blood and intracellular fluids are drained and replaced with a medical cryoprotectant so tissues remain viable for long-term storage. The goal is to protect neural and other cells during transport to the preservation facility, and to begin the cooling process in a controlled way. Cooling proceeds in stages, avoiding premature freezing that would damage cells. The body is gradually cooled to just above freezing and then to temperatures compatible with liquid nitrogen. Final storage occurs at minus 196 Celsius (minus 320 Fahrenheit) in vacuum-insulated aluminum vessels. Some members opt for whole-body preservation, others for neuro preservation with the brain kept inside the skull. The process is technically demanding, and revival remains uncertain; major challenges include rewarming without ice recrystallization, which can damage cells. The conversation emphasizes that revival depends on advances in brain repair, organ and tissue regeneration, and, potentially, nanotechnology, rather than any single breakthrough. A central concept discussed is information-theoretic death: legal and clinical death may occur even when meaningful information persists in the brain, making revival conceivable in principle if enough information remains. The interview notes that future revival likely hinges on breakthroughs such as lab-grown organs, regenerative therapies, and nanoscale machines that could repair tissue and restore function. Alcor frames cryonics as an extension of emergency medicine rather than immortality; it seeks to preserve life for a future era when technology could restore it. Alcor’s organizational model is nonprofit, funded largely by life insurance. Membership runs around six hundred dollars annually, and the cryopreservation fee for a whole body starts at two hundred thousand dollars, while neuro preservation begins at eighty thousand. Most members use life insurance to fund these costs, and a dedicated patient care fund endows long-term preservation with restrictions on withdrawals. Alcor stores approximately 196 human patients and about 100 pets, mostly in Scottsdale, Arizona, chosen for environmental stability and a history of legal stability after earlier California challenges, including the Dora Kent case in 1988. The facility offers tours, publishes case reports for transparency, and emphasizes patient rights, with public and private storage options. Ted Williams and Hal Finney are noted as prominent public or well-known patients linked to cryonics. The discussion also covers social and philosophical implications: the possibility of future space-based living communities, the rejuvenation of the body to avoid aging, and the ethical and legal questions surrounding long-term preservation. Practical cautions include planning well in advance, the difficulty of last-minute cases, and the necessity of clear contracts and governance designed for longevity. The guest reflects on the evolving meaning of death, the potential for future technologies to repair or replace tissues, and the idea that cryonics represents a long-term, informed gamble on life, health, and the possibility of returning to a future world.

Dr. Crawford explains that an anti-Müllerian hormone (AMH) test, while not a measure of egg quality, estimates remaining egg quantity and can meaningfully inform a person's reproductive timeline and health planning. She emphasizes that fertility is a health marker reflecting hormonal, metabolic, and cellular health, and discusses how fertility status intersects with long-term risks such as metabolic syndrome and cardiovascular disease. The conversation covers menopause and perimenopause, clarifying that ovulatory cycles can still occur and that hormone replacement therapy can be appropriate earlier than traditionally assumed to alleviate symptoms and confer long-term health benefits. The hosts and guest stress the importance of understanding egg biology: eggs originate in a finite ovarian pool, age-related mitochondrial and chromosomal changes influence egg quality, and AMH gives a population-level sense of reserve rather than a precise prediction of pregnancy. They argue for a proactive, individualized approach to fertility and health that includes tracking ovulation, evaluating endocrine function when needed, and considering interventions (like IVF or egg freezing) earlier when reserve is low. The dialogue also delves into toxin exposure and inflammation as modifiable determinants of reproductive health, with practical guidance on sleep, diet, and lifestyle to reduce inflammatory burden and optimize hormonal balance. The discussion moves to the realities of fertility treatments, including how IVF and egg freezing work, why egg count does not deplete faster because of stimulation, and how better data and access can empower autonomous decision-making. They examine the role of supplements—Coenzyme Q10, omega-3s, and other nutraceuticals—within a broader strategy that prioritizes core lifestyle factors first, while acknowledging that individual responses vary. The episode further explores public health and ethical dimensions of fertility care, including insurance coverage, ethical considerations around embryo disposition, and the evolving willingness of the medical community to pursue proactive fertility preservation and optimization. Throughout, the guests share personal experiences to illuminate patient-centered care, and emphasize that listening to one’s body, tracking cycles, and making informed, timely decisions can meaningfully shape reproductive outcomes and overall health.

Megyn Kelly opened the show discussing the South Carolina primary results, where Donald Trump won by 20 points over Nikki Haley, a predictable outcome. Both candidates claimed to find positive aspects in the results. The conversation shifted to developments in Georgia involving Trump and Fulton County DA Fanny Willis. Trump's team filed a motion alleging that Willis and her lover, Nathan Wade, lied about the timeline of their affair, claiming evidence of their relationship dating back to 2021, contrary to their assertions that it began in 2022. This included cell phone records showing numerous visits and communications between the two. Phil Holloway, a legal expert, joined the discussion to explain the implications of the ongoing legal battles surrounding this case. He highlighted the importance of determining whether communications between Wade and his attorney, Terence Bradley, are protected by attorney-client privilege. The judge is expected to review evidence in a closed session to assess the validity of these claims. Holloway noted that the longer the state fights to keep this information out, the more it raises questions about potential conflicts of interest and fairness in the prosecution. The conversation then shifted to a tragic incident involving a young nursing student, Laken Riley, who was murdered by an illegal immigrant, Jose Antonio Ibarra. This incident sparked discussions about immigration policies and the consequences of lax border security. The panel expressed outrage over the failure to detain individuals with criminal records and the broader implications for public safety. The show also covered the implications of a recent Alabama court ruling that has disrupted IVF practices in the state. The ruling classified the loss of frozen embryos as wrongful death, causing panic among IVF clinics and affecting families seeking to conceive. The panel discussed the ethical considerations surrounding IVF and the need for clearer legal frameworks to protect families and their embryos. In closing, the discussion highlighted the political ramifications of these issues, particularly how they may affect Republican candidates in upcoming elections. The need for a balanced approach to pro-life policies that also supports reproductive technologies like IVF was emphasized as crucial for appealing to a broader voter base.

In this discussion, Ross Douthat interviews Noor Siddiqui, founder of Orchid, a Silicon Valley startup focused on advanced genetic screening for embryos. Siddiqui explains that Orchid allows parents to sequence the entire genome of embryos, providing comprehensive information about potential health risks, including serious conditions like heart defects and pediatric cancers. This technology aims to empower parents to make informed decisions before pregnancy, shifting the current IVF process, which often relies on limited genetic testing. Siddiqui emphasizes that this service is not just for older or high-risk parents but is beneficial for anyone wanting to protect their future children. The process involves IVF, where embryos are created, and a portion of their cells is sent to Orchid for analysis. The results include chromosomal analysis and screening for over 1,200 monogenic disorders, as well as polygenic risk scores for conditions influenced by multiple genes. Siddiqui acknowledges the ethical implications of embryo selection and the potential societal impact of widespread genetic screening. She argues that while embryos are precious, the technology can help prevent suffering from genetic diseases. The conversation touches on the moral status of embryos, with Siddiqui asserting that parents should have the freedom to make choices based on the health of their future children. The discussion also raises concerns about the potential for a genetic divide based on socioeconomic status, with Siddiqui advocating for broader access to IVF and genetic screening technologies. Ultimately, she believes that informed choices about embryo selection can lead to healthier future generations, while also recognizing the importance of personal agency in reproductive decisions.

Fibroids are described as common benign tumors with higher prevalence in Black women, potentially linked to vitamin D deficiency, and capable of causing heavy bleeding, pelvic pressure, pain, and infertility when they invade the uterine lining. The conversation centers on fertility barriers and practical actions people take that can influence outcomes. The guest emphasizes that awareness and early discussion about fertility are crucial, noting that lifestyle choices such as smoking can accelerate menopause and harm egg quality, while heart-healthy diets and muscle-building can improve insulin sensitivity and reproductive prospects. The discussion expands to both partners' roles in fertility, underscoring that male health, environmental exposures, and metabolic health can affect placental function and pregnancy success. The host and guest analyze the biology of aging in eggs, the slower decline of male sperm quality, and how paternal factors can influence embryo viability and placental development, highlighting the importance of shared responsibility in trying to conceive. The dialogue also covers practical tests and interventions: semen analysis, pelvic ultrasounds, tubal testing, hormone profiling, and AMH as a count rather than a precise fertility predictor. It discusses IVF strategies, such as single-embryo transfer to reduce multiples, genetic testing considerations, and the controversial ethics of embryo sex selection. The guest cautions against fertility myths propagated online, urges critical evaluation of extraordinary claims, and argues for preconception planning and a proactive approach to reproductive health. They advocate for better access to information, earlier consultation, and a shift away from blaming women alone for fertility challenges, while acknowledging that luck and biological timing still play significant roles. The episode culminates with the guest promoting her book and suggesting the future potential for breakthroughs that could extend reproductive windows, along with practical resources and social media links for listeners seeking more information.

The podcast explores embryo selection and polygenic screening, a technology developed by Herasite. Jonathan Anomaly clarifies that this process, distinct from gene editing, provides comprehensive genetic information about embryos during IVF, allowing parents to select based on polygenic traits like disease risk (e.g., schizophrenia, diabetes), intelligence, and height. This is achieved by reconstructing the full embryo genome from existing PGTA data and parental whole-genome sequencing, effectively democratizing access by reducing reliance on individual doctors' understanding. Anomaly addresses public apprehension, which often confuses embryo selection with gene editing or historical eugenics. He emphasizes the distinction between individual informed choice and coercive government control, noting that Herasite champions the former. Cultural differences in acceptance are highlighted, with Asian societies showing less moral distinction between screening for disease and positive traits compared to Western nations, where post-WWII taboos persist. Concerns about widening genetic inequality between socioeconomic groups are discussed; Anomaly suggests that while initial access might be limited, technology typically becomes more affordable over time. He argues against government subsidies, fearing it could lead to mandatory participation and infringe on individual autonomy, drawing parallels to debates around public health mandates. The conversation delves into the "ickiness" often associated with genetics, which is frequently misconstrued as deterministic or judgmental. Anomaly posits that understanding genetics can be empowering, helping minimize disease burden and optimize for well-being. He tackles the "non-identity problem," explaining that choosing a different embryo means a different person is born, thus reframing parental "remorse" or "culpability." He uses analogies like preventing fetal alcohol syndrome or vaccinating children to argue that making choices to improve future offspring's prospects is morally sound. Anomaly underscores the critical need for transparency and scientific validation of polygenic scores, particularly across diverse ancestries, to combat misleading claims by some companies. Herasite's research indicates "positive pleiotropy," where selecting against one disease often reduces risks for others, and intelligence correlates with numerous beneficial life outcomes. Regarding ethical boundaries, Anomaly suggests companies should refuse selection for clearly antisocial traits (e.g., sadism, psychopathy) or severe, debilitating conditions like Tay-Sachs, believing social norms are powerful deterrents. He differentiates the moral status of an undifferentiated embryo from a developed fetus, citing the high rate of natural spontaneous abortions due to genetic abnormalities. The discussion concludes with the technology's inevitability, its potential to challenge the "blank slate" view of human nature, and the geopolitical implications as nations adopt varying approaches.

Orchid’s founder Noor Siddiqui discusses the transformative potential and ethical contours of whole-genome embryo screening, a technology that gives parents far more information about their embryos during IVF than the traditional 1% genome view. She explains that Orchid enables screening for thousands of genetic conditions across the genome, allowing couples to compare embryos by their calculated genetic risk and to select those with substantially lower projected disease burdens. This shifts the decision-making from a subjective, morphology-based “beauty contest” to a data-driven process aimed at reducing risks of pediatric cancers, neurodevelopmental disorders, and complex diseases influenced by many variants. Noor frames this as a way to genetically bless a child and to move health risk earlier, before pregnancy is fully underway, which she believes can dramatically improve lifelong outcomes for families. topicsList fromTranscriptWeed out health risks through embryo screening, genetic risk scores, IVF economics and access, regulatory and societal implications, emotion and meaning in pregnancy, historical panic around new technologies, patient-led adoption, global differences in IVF uptake, future traits like intelligence and non-health attributes, ethical considerations, love and trust in the Orchid community. otherTopicsList fromTranscriptSocietal debate about information ethics, information hazard and parental autonomy, international fertility tourism and cross-border access, private versus public funding for IVF and embryo screening, the emotional toll of miscarriages and congenital diagnoses, the evolution of reproductive technology and moral panics, the role of patient advocacy in driving adoption, potential unintended consequences of widespread screening, the idea of “ethical black box” in genetics, the contrast between health benefits and cosmetic trait preferences